Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Kathy S. Albain(Loyola University Chicago), Laura J. Esserman(University of California, San Francisco), Constantine Godellas(Loyola University Chicago), Rita Nanda(University of Chicago), Angela DeMichele(University of Pennsylvania), Denise M. Wolf, Henry G. Kaplan(Swedish Medical Center), Adam L. Asare(Quantum Leap Healthcare Collaborative), Lajos Pusztai(Yale University), Scott Berry(Queen's University), Lamorna Brown Swigart(University of California, San Francisco), Amy Wilson(Quantum Leap Healthcare Collaborative), Julia Wulfkuhle(University of California, San Francisco), Rachel L. Yung(Seattle Cancer Care Alliance), Tufia C. Haddad(Mayo Clinic), Ruby Singhrao(University of California, San Francisco), Janice Lu(University of Southern California), Judy C. Boughey(Mayo Clinic in Arizona), Douglas Yee(University of Minnesota Medical Center), Nola M. Hylton(University of California, San Francisco), Julie E. Lang(University of Southern California), Julia L. Clennell(Berry & Associates (United States)), Erica Stringer-Reasor(University of Alabama at Birmingham), David Euhus(The University of Texas Southwestern Medical Center), Smita Asare(Quantum Leap Healthcare Collaborative), Yunn‐Yi Chen(University of Vermont), Meredith Buxton(Center for Effective Global Action), A. Jo Chien(University of California, San Francisco), Sarah L. Blair(University of California San Diego), Rosa I. Gallagher(The University of Texas MD Anderson Cancer Center), Christina Yau(Hospital Authority), Amy S. Clark(Abramson Center for Jewish Life), Jeffrey B. Matthews(University of California, San Francisco), Claudine Isaacs(Georgetown University), Jane Perlmutter(Gemini Computers (United States)), Donald A. Berry(Berry & Associates (United States)), Gillian L. Hirst(University of California, San Francisco), David A. Potter(Indiana University – Purdue University Indianapolis), Andres Forero-Torres(University of Alabama at Birmingham), Hope S. Rugo(City of Hope), Anne M. Wallace(University of California San Diego), Anthony Elias(University of Colorado Cancer Center), Gregor Krings(Cleveland Clinic), Ashish Sanil(Berry & Associates (United States)), Laura J. van’t Veer(University of California, San Francisco), Debu Tripathy(The University of Texas MD Anderson Cancer Center), Michelle Melisko(University of California, San Francisco), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center)
Cited by 20
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k